ArticleMicrobial cell factories2026
High-copy plasmid engineering enhances recombinant protein and antimicrobial peptide production in Corynebacterium glutamicum.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial peptides (AMPs) such as pediocin PA-1 are attractive for food biopreservation and infection control, but their broader use is limited by low recombinant yields and high production costs. Corynebacterium glutamicum has emerged as a robust GRAS chassis for heterologous peptide and protein production, yet commonly used shuttle vectors provide only moderate plasmid copy numbers and expression capacities. In particular, existing pediocin PA-1 processes in C. glutamicum rely on standard pBL1- or pCG1-family vectors that do not yet leverage replication-origin engineering.
resultsWe rationally redesigned the replication control region of the widely used pClik 5α (pCG1-family) backbone by introducing targeted mutations in the repA gene, an antisense RNA (cgrI) promoter, and putative partitioning genes parAB, and constructed a systematic panel of high-copy variants. Using a Ptuf-driven mCherry reporter as a quantitative readout, we identified plasmids that supported several-fold higher fluorescence than the parental backbone while maintaining robust growth. Fluorescence-based gene-dosage estimation indicated a strong increase in apparent plasmid copy number. Independent qPCR-based plasmid copy number determination using two plasmid loci confirmed that the lead variant pClik 5α repAmut reached approximately 28–30 copies per chromosome equivalent, compared to approximately 2–3 copies for the parental plasmid, corresponding to an approximately 10-fold increase. Genome-wide transcriptome analysis revealed a defined and adaptive transcriptional response to elevated plasmid copy number and expression burden, characterized by adjustments in membrane-associated transport, respiratory functions, and amino acid-related metabolism, without evidence of collapse of core biosynthetic functions. When the best-performing replicon was applied to episomal expression of a codon-optimized pedACDCgl operon, pediocin PA-1 titers increased by 2.5-fold compared to the best pXMJ19-based reference under identical, previously optimized process conditions, placing the system, under comparable cultivation formats, within the upper range of reported microbial pediocin production processes.
conclusionsThis work demonstrates that rational engineering of pCG1-family replication modules in C. glutamicum can unlock markedly higher plasmid copy numbers and expression capacities while preserving physiological robustness. The resulting high-copy pClik 5α derivatives, exemplified by pClik 5α repAmut, provide a versatile high-copy expression platform with demonstrated utility for recombinant reporter protein and antimicrobial peptide production in C. glutamicum and offer a foundation for further integration with folding, secretion, and process engineering strategies to advance industrial AMP production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.